A US family office is among the investors in a new weight loss pill that aims to treat obesity, weight issues and diabetes in a non-invasive way.
Clinical stage company Gelesis raised $12 million (€8.7 million) in its latest round of fundraising to develop its lead product Gelesis100.
The pill is designed to suppress feelings of hunger without the use of invasive procedures, such as surgery.